Mark Awad

Jan 8, 2025 | brnw.ch | Mark Awad |Patrick M. Forde |Jonathan Spicer

IntroductionPD-(L)1 immune checkpoint inhibitor–based regimens have recently expanded neoadjuvant and adjuvant treatment options for resectable non–small cell lung cancer (NSCLC). Nivolumab, a PD-1 antibody, combined with chemotherapy is now a standard neoadjuvant treatment for eligible patients with resectable NSCLC.

Oct 3, 2024 | onclive.com | Mark Awad

Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the significance of the FDA approval of perioperative nivolumab (Opdivo) for patients with resectable non–small cell lung cancer (NSCLC).